Featured News

Germanwings pilot Andreas Lubitz wrote, in a desperate, final email to his psychiatrist two weeks before slamming his A320 jet into the French Alps...

Two recent court rulings argue that pharmaceutical companies have a first amendment right to market drugs “off-label” with a lack of scientific evidence, threatening...

Despite concerns about the risk to benefit ratio, the FDA approved flibanserin (Addyi) to treat low female sexual desire in August. In a new...

A recent article in the American Journal of Public Health calls for policy level interventions to reduce the use of benzodiazepines, drugs commonly prescribed...

A new study tracks the approval of the latest antidepressant, vortioxetine, by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA). The...

A recent review of the research found that benzodiazepine use may have long-term effects on memory and increase the risk for dementia. The study,...

There is a substantial body of evidence suggesting that not getting enough omega-3 fatty acids in your diet may be connected to a diverse array of psychiatric symptoms. In a new study published this month, psychiatrist Robert McNamara and Erik Messamore provide an overview of the evidence and call for screening of omega-3 deficiency in people experiencing symptoms associated with ADHD, depression, mood disorders, and psychosis.

A pathbreaking new study out of Finland suggests that early intervention programs for youth experiencing psychotic-like symptoms may see the greatest improvement when treatment works within the home rather than in a hospital setting. The research, to be published in next month’s issue of Psychiatry Research, found greater improvement in functioning, depression, and hopelessness among teens in a new need-adapted Family and Community oriented Integrative Treatment Model (FCTM) program.

A study published in this month’s issue of the Social Psychiatry and Psychiatric Epidemiology found that perceived discrimination related to minority status may precede...

A recent review of the evidence by the American College of Physicians (ACP) determined that cognitive behavioral therapy and antidepressants had similar levels of effectiveness for the treatment of depression. In a critical commentary for the Journal of Mental Health, however, Michael Sugarman from Wayne State University challenges these findings. Pointing to differences in research settings and clinical practice, Sugarman asserts that “these head-to-head comparisons are heavily biased in the direction of psychiatric care.”

While antidepressants are the most commonly used long-term treatment for depression, the efficacy of these drugs after one year is unknown. In a commentary for The Lancet, psychiatrists Rudolf Uher and Barbara Pavlova suggest that cognitive behavioral therapy (CBT) now has the most substantial body of evidence for long-term treatment for major depressive disorder.

A combination of exercise and meditation done twice a week over two months may reduce depression symptoms by 40 percent, according to a new study published open-access this month in Translational Psychiatry. Following the eight-week intervention, the student participants that had previously been diagnosed with major depressive disorder (MDD) reported significantly less symptoms and ruminative thoughts and students without any such diagnoses also showed remarkable improvements.

Following an extensive systematic review of treatments for major depression, the American College of Physicians (ACP) issued a recommendation to clinicians suggesting cognitive behavioral therapy (CBT) as a first-line treatment for major depressive disorder along with second-generation antidepressants. The results of the review revealed that CBT and antidepressants have similar levels of effectiveness but that antidepressants present serious side-effects and higher relapse rates.

After undergoing a nine-week cognitive behavioral therapy (CBT) treatment for social anxiety, patients show changes to both the physical structure of their brain and its activity, according to a new study published in Translational Psychiatry. The amygdala is most closely associated with the experience of fear and this study found that patients receiving CBT with reduced social anxiety had significant changes to this section of the brain.

A study published in this month’s issue of the Journal of Clinical Psychiatry found that the use of antidepressant drugs was associated with an...

In a scathing editorial in this month’s Psychotherapy and Psychosomatics, Dr. Giovanni Fava takes aim at prominent medical experts who have downplayed the role...

In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...

Dutch psychiatrist and epidemiologist, Jim van Os, has renewed his call to drop schizophrenia as a disease classification. “Several recent papers by different authors...

Richard Smith, the chair of the board of trustees at BMJ, penned an editorial yesterday bringing increased scrutiny to research misconduct and medical fraud in the UK. Smith identifies denial about the seriousness of the problem and the reluctance of universities to submit themselves to reviews as the two major reasons that Britain has failed to address these issues.

Psychologist and Professor Amber Gum has published the story of her personal journey of rethinking psychotropic medication in a special issue on "The Politics of Mental Health" in The Journal of Medicine and the Person. Influenced by Mad in America and the work of Robert Whitaker, Gum became aware of evidence that “suggests that psychotropic medications are less effective and more harmful than most believe” and now hopes to encourage other mental health professionals and researchers to engage in open-minded, critical self-assessment of standard practices.

The largest-ever meta-analysis of antidepressant trials appeared yesterday in the British Medical Journal. Researchers from the Cochrane Collaboration reviewed 70 trials (involving 18,526 subjects), to find that - counter to the initially-reported findings - antidepressants doubled the risk of suicide and aggression in subjects under 18. This risk had been misrepresented in the original study reports, the authors say, and suggest that the risks to adults may be similarly under-reported.

Public health researchers at the University of Western Australia examined the relationship between recreational arts engagement and mental well-being in the general population. The results, which have implications for policy makers as well as health practitioners, indicate that those who engage with the arts for two or more hours per week have significantly better mental well-being.

“Overall, this study showed that the information and awareness campaign had almost no significant effects on the general public's attitudes toward people affected by either schizophrenia or depression,” the researchers, led by German medical sociologist Anna Makowski, wrote. “One could assume that deeply rooted convictions cannot be modified by rather time-limited and general activities targeted at the public.”

A study published in this month’s issue of Stroke found that antidepressants may increase the risk of microbleeds in the brain. Both SSRI and SNRI antidepressants can disrupt natural clotting mechanisms and lead to increased adverse bleeding incidents and prolonged bleeding times.

According to new research by Joanna Moncrieff and Sebastião Viola, mental health problems have become the leading cause of disability claims in the UK. While the overall number of claims for other conditions has decreased by 35%, claims related to “mental disorders” have increased 103% since 1995.